Introduction
Hepatocellular carcinoma (HCC) remains among the most prevalent and deadly cancers worldwide, ranking as the sixth most common and the third leading cause of cancer mortality. Its multifactorial etiology involves persistent viral infections such as hepatitis B virus (HBV) and hepatitis C virus (HCV), chronic alcohol consumption, and metabolic liver diseases like MASLD. Of particular concern is the synergistic effect of alcohol and HBV infection in accelerating hepatic carcinogenesis.
This article discusses recent advances from Zhou et al., published in the Journal of Hepatology, which uncover novel molecular mechanisms by which alcohol exacerbates HBV-related HCC. Emphasizing the role of lipid metabolism reprogramming and ER stress, these findings illuminate innovative therapeutic avenues.
Study Background and Disease Burden
HCC develops in a diseased liver often marked by chronic inflammation, fibrosis, and genetic alterations. In HBV-endemic regions, infection acts as a primary trigger, with alcohol further aggravating hepatic injury and carcinogenesis. The complex pathogenesis involves oxidative stress, lipotoxicity, and epigenetic dysregulation, compounding disease severity. Despite existing therapies, prognosis remains poor, necessitating identification of specific molecular targets.
Study Design and Methods
Zhou et al. employed a transgenic mouse model expressing HBx protein, a key regulator in HBV pathogenesis. Using these HBx-transgenic mice, the researchers implemented chronic ethanol feeding strategies to mimic alcohol consumption in humans. They performed lipidomic analyses, transcriptomics, and cellular experiments, including gene knockdowns using shRNA in HepG2.215 hepatoma cells. The study aimed to elucidate the cellular pathways activated by ethanol and HBV interplay.
Key endpoints included the evaluation of lipid species, particularly bis(monoacylglycero)phosphate (BMP), expression levels of lysosomal phospholipase A2 (LPLA2), ER stress markers, and tumor development metrics.
Major Findings
Zhou et al. demonstrated that chronic alcohol intake significantly accelerates spontaneous HCC development in HBx-mice, indicating a ‘second hit’ effect. Lipidomic profiling identified a marked increase in BMP levels in tumor tissues of ethanol-fed mice, which correlates with lysosomal alterations. Further analysis revealed upregulation of LPLA2, an enzyme responsible for BMP accumulation, driven by ethanol-induced ER stress.
Mechanistically, ethanol and its metabolite acetaldehyde induce ER stress, activating transcription factor ATF4 that binds to the promoter of PLA2G15, encoding LPLA2, enhancing its expression. Elevated LPLA2 promotes BMP accumulation, which supports tumor cell proliferation by activating the MAPK/ERK pathway.
Functional experiments confirmed that knocking down LPLA2 in hepatoma cells reduces BMP levels and inhibits proliferation, while overexpression of BMP synthase CLN5 promotes tumor growth. Importantly, in human HCC tissues, LPLA2 expression was higher than in non-tumor tissues, and its levels correlated with worse prognosis and advanced disease, especially in patients with concurrent HBV and alcohol consumption.
Discussion and Clinical Implications
This study offers compelling evidence that alcohol fuels a pathogenic cascade involving ER stress and lipid reprogramming to promote HBV-associated HCC. The identification of LPLA2 and BMP as potential therapeutic targets is significant, as these molecules are instrumental in tumor cell survival and proliferation.
While the study is innovative, limitations include the use of a spontaneous HBx transgenic mouse model, which may not fully capture the complexity of human ALD-HCC. Additionally, the mechanistic details linking BMP to MAPK/ERK activation require further elucidation.
Targeting enzymes involved in BMP metabolism, such as LPLA2 or CLN5, could lead to new strategies for intervention. Moreover, measuring serum LPLA2 or BMP levels might serve as prognostic biomarkers for disease progression, especially in HBV patients with alcohol use.
Conclusions
The research underscores alcohol’s role in aggravating HBV-related HCC via a novel pathway involving ER stress and lipid metabolic reprogramming. Therapeutic modulation of LPLA2 and BMP metabolism presents promising opportunities for reducing disease burden and improving patient outcomes. These findings also reinforce the clinical importance of alcohol abstinence in HBV-infected individuals.
Future investigations should focus on validating these targets in clinical trials and exploring the broader applicability across different liver disease models. Integrating molecular insights with clinical practice may facilitate personalized therapies and better prognostication in HBV-HCC.
References
1. Qian S, He Y. Alcohol consumption potentiates second-hit events in HBV-induced hepatocellular carcinoma. J Hepatol. 2025;10:S0168-8278(25)02548-6.
2. Additional relevant references from the literature on HBV, alcohol, and lipid metabolism in HCC.